2. KARINA HALFEN 2
Intercepting Chagas disease is a win-win-win between
J&J, governments and population
Endemic Non endemic but present
AS IS TO BE
Note: (1) DALYs = Disability Adjusted Life Years. The sum of years of potential life lost due to premature mortality and the years of productive life lost due
to disability.
Sources: Drugs for Neglected Disease Initiative, World Health Organization.
8 million cases
430.000 DALYs¹ – more than 1.100 years
$ 7 billion dollars spent
In one market: Bolivia
$ 23mi profit for J&J
$ 79mi dollars saved by the public
health system
Impact on more than 3 million lives
20 more markets to go
3. KARINA HALFEN 3
Chagas: Reversing the status of neglected
disease
Disease stats
$255M Cost of Chagas (Bolivia)
1.8M Bolivians with Chagas (15% of population)
45,000 Deaths a year in Bolivia
Chagas disease has available medications, but it’s critical that is identified in an early stage.
The main problem is diagnosing, as most infected individuals are not aware of their status.
Interception
vision
ID RISK
MONITOR INTERVENE
•
Pheromones detection
•
Gel – blood test
•
Available
medicines
Potential
collaborators
Bolivian
government: agree
to pay for monitor
costs
Logistics: distribute
the gel to people in
remote areas
4. KARINA HALFEN 4
Call for action – some questions
•
Sent people abroad to work on Chagas disease in Bolivia
•
After investing so much, are you willing to help
intercept Chagas?
•
How do you feel about saving $79 million and
intercepting your fourth most common disease?
•
Do you want to profit $23 million and impact the
lives of 3 million people? If this is a success there’s
the possibility to approach 20 more markets.
•
We need a team of scientists, business analysts,public
relations and lawyers.
•
Initially, for the R&D, we need $ 55 Million
0.3% of J&J revenues to make an impact on 3 million lives.
